Clinical validity of 25-gauge endobronchial ultrasound-guided transbronchial needle in lymph node staging of lung cancer.
Bronchoscopy
lung cancer
lymph nodes (LNs)
staging
transbronchial needle aspiration
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
24
6
2021
pubmed:
25
6
2021
medline:
25
6
2021
Statut:
ppublish
Résumé
Endobronchial ultrasound-guided transbronchial needle aspiration is recommended for lymph node (LN) staging in lung cancer. Although 22-gauge needles are widely used, they may make some stations difficult to puncture owing to an acute angle. A thinner 25-gauge needle was introduced in Japan at the end of 2016 and offered structural advantages such as improved flexibility and penetrability. We aimed to validate the clinical utility of the 25-gauge needle in LN staging. Patients who underwent endobronchial ultrasound-guided transbronchial needle aspiration for LN staging of lung cancer using the 25-gauge needle at our institution between November 2016 and March 2019 were included. Patient characteristics, staging procedures, pathology findings, and genetic testing success rates were assessed. Data of 130 patients were included in the analysis. The sampling rate was 87.6% (589/672 lesions). In addition to stations #4R, #7, and #11, which are generally easy to puncture, multiple stations (40.1%) were sampled. The diagnostic accuracy of combined computed tomography and fluorodeoxyglucose positron emission tomography was 82.3% and that of additional endobronchial ultrasound-guided transbronchial needle aspiration was 96.9%. The overall sensitivity, specificity, and positive and negative predictive values validated using resected specimens were 97.1% (34/35), 100% (41/41), 100% (34/34), and 97.6% (41/42), respectively. The success rate of genetic testing was 100% (34/34). The new 25-gauge needle enabled us to approach a wide range of LNs with a desirable sampling rate and diagnostic accuracy in LN staging using endobronchial ultrasound-guided transbronchial needle aspiration, while providing enough tissue for genetic testing.
Sections du résumé
BACKGROUND
BACKGROUND
Endobronchial ultrasound-guided transbronchial needle aspiration is recommended for lymph node (LN) staging in lung cancer. Although 22-gauge needles are widely used, they may make some stations difficult to puncture owing to an acute angle. A thinner 25-gauge needle was introduced in Japan at the end of 2016 and offered structural advantages such as improved flexibility and penetrability. We aimed to validate the clinical utility of the 25-gauge needle in LN staging.
METHODS
METHODS
Patients who underwent endobronchial ultrasound-guided transbronchial needle aspiration for LN staging of lung cancer using the 25-gauge needle at our institution between November 2016 and March 2019 were included. Patient characteristics, staging procedures, pathology findings, and genetic testing success rates were assessed.
RESULTS
RESULTS
Data of 130 patients were included in the analysis. The sampling rate was 87.6% (589/672 lesions). In addition to stations #4R, #7, and #11, which are generally easy to puncture, multiple stations (40.1%) were sampled. The diagnostic accuracy of combined computed tomography and fluorodeoxyglucose positron emission tomography was 82.3% and that of additional endobronchial ultrasound-guided transbronchial needle aspiration was 96.9%. The overall sensitivity, specificity, and positive and negative predictive values validated using resected specimens were 97.1% (34/35), 100% (41/41), 100% (34/34), and 97.6% (41/42), respectively. The success rate of genetic testing was 100% (34/34).
CONCLUSIONS
CONCLUSIONS
The new 25-gauge needle enabled us to approach a wide range of LNs with a desirable sampling rate and diagnostic accuracy in LN staging using endobronchial ultrasound-guided transbronchial needle aspiration, while providing enough tissue for genetic testing.
Identifiants
pubmed: 34164194
doi: 10.21037/jtd-20-3383
pii: jtd-13-05-3033
pmc: PMC8182540
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3033-3041Informations de copyright
2021 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-3383). The authors have no conflicts of interest to declare.
Références
J Natl Compr Canc Netw. 2015 May;13(5):515-24
pubmed: 25964637
J Thorac Dis. 2017 Sep;9(9):E762-E766
pubmed: 29221338
Ann Intern Med. 2003 Dec 2;139(11):879-92
pubmed: 14644890
Radiology. 1992 Feb;182(2):319-23
pubmed: 1732943
Radiol Clin North Am. 2012 Sep;50(5):935-49
pubmed: 22974779
Respir Res. 2013 May 10;14:50
pubmed: 23663438
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Lancet. 2002 Apr 20;359(9315):1388-93
pubmed: 11978336
Jpn J Clin Oncol. 2014 Oct;44(10):956-62
pubmed: 25121724
J Thorac Dis. 2019 Aug;11(8):3643-3649
pubmed: 31559072
Lung Cancer. 2005 Dec;50(3):347-54
pubmed: 16171897
Lancet Respir Med. 2016 Dec;4(12):960-968
pubmed: 27773666
Chest. 2010 Sep;138(3):641-7
pubmed: 20382710
Int J Cancer. 2013 Jan 15;132(2):E37-47
pubmed: 22890912
Clin Lung Cancer. 2018 May;19(3):230-238.e2
pubmed: 29277564
Chest. 2017 Mar;151(3):636-642
pubmed: 27769775
Ann Thorac Surg. 2005 Jan;79(1):375-82
pubmed: 15620991
Chest. 2007 Sep;132(3 Suppl):178S-201S
pubmed: 17873168
J Cancer Res Ther. 2019;15(7):1490-1495
pubmed: 31939427
Endoscopy. 2011 Aug;43(8):709-15
pubmed: 21611946
Eur J Cancer. 2013 May;49(8):1860-7
pubmed: 23481511
J Bronchology Interv Pulmonol. 2018 Apr;25(2):e17-e19
pubmed: 29561399
Ann Thorac Surg. 2013 Oct;96(4):1502-1507
pubmed: 23993894
Dig Dis Sci. 2013 Apr;58(4):1026-34
pubmed: 23086117
Eur J Cancer. 2009 May;45(8):1389-96
pubmed: 19124238
J Korean Med Sci. 2012 Jan;27(1):46-51
pubmed: 22219613
Scand J Gastroenterol. 2013 Jun;48(6):752-7
pubmed: 23600919
Chest. 2018 Apr;153(4):929-938
pubmed: 29154972
Am Rev Respir Dis. 1990 May;141(5 Pt 1):1096-101
pubmed: 2160211
Chest. 2016 Mar;149(3):816-35
pubmed: 26402427
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
J Thorac Oncol. 2012 Jun;7(6):1009-14
pubmed: 22525556
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Pulm Med. 2016;2016:1024709
pubmed: 27818796